Abstract: A method for imaging a tissue of an eye, the method including the steps of providing oblique illumination to the eye by a plurality of light emitting areas of a light delivery device, the plurality of light emitting areas being independently controllable and arranged to direct light towards at least one of a retina and an iris of the eye, causing an output beam from light backscattered from the at least one of the retina and the iris by the oblique illumination, capturing the output beam with an imaging system to provide a sequence of images of a fundus of the eye, and retrieving a phase and absorption contrast image from the sequence of images of the fundus, wherein the sequence of images of the fundus of the step of capturing is obtained by sequentially turning on one or more of the plurality of light emitting areas at a time in the step of providing the oblique illumination.

Abstract: Central Serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium. To date, no systemic biomarker of CSCR have been discovered that could link both forms and help the diagnosis in challenging cases. In the present invention, the inventors measure in European cohorts of CSCR patients (n=168) with (n=90) or without epitheliopathy (n=78) and a cohort of 153 control subjects without any ocular disease history, the serum levels of NGAL and the NGAL/MMP9 complex. Serum NGAL (ng/ml) was significantly higher in the control group (108.8±46.8) than in the CSCR cohort (80.4±46.4, p<0.0001). Serum NGAL (ng/ml) was significantly lower in the acute/recurrent cohort (n=78, 71.3±32.1) than in the control and, than in the chronic cohort (n=90, 88.3±55, p=0.03). Similarly, Serum NGAL/MMP9 (ng/ml) levels was lower in the whole CSCR cohort (44.5±39.6) as compared to the controls (77.6±47.8, p<0.0001).

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of choroddal neovascularisation. In particular, the present invention relates to a method of treating choroidial neovascularisation in a subject in need thereof comprising administering to the subject of therapeutically effective amount of a mineralocorticoid receptor antagonist.

Abstract: A device including a support (4) comprising a support base defining a spherical base contact surface, extending along a virtual sphere (S) and a circular rim extending in a rim plane; a first and a second needle mobile on the support between extracted and inserted positions in which the first and second needles are outside and maximally inserted in said virtual sphere, respectively, via first and second intermediate piercing positions in which, respectively, the first and second needles extend along first and second insertion axis and their tips are located on first and second insertion points belonging respectively to first and second hemispheres of the virtual sphere separated by a “median radial plane of the rim”, an angle (?) between the median radial plane and any insertion axis being between 70° and 110°.

Abstract: A method for imaging a tissue of an eye, the method including the steps of providing oblique illumination to the eye by a plurality of light emitting areas of a light delivery device, the plurality of light emitting areas being independently controllable and arranged to direct light towards at least one of a retina and an iris of the eye, causing an output beam from light backscattered from the at least one of the retina and the iris by the oblique illumination, capturing the output beam with an imaging system to provide a sequence of images of a fundus of the eye, and retrieving a phase and absorption contrast image from the sequence of images of the fundus, wherein the sequence of images of the fundus of the step of capturing is obtained by sequentially turning on one or more of the plurality of light emitting areas at a time in the step of providing the oblique illumination.

Abstract: A method for imaging a tissue of an eye, the method including the steps of providing oblique illumination to the eye by a plurality of light emitting areas of a light delivery device, the plurality of light emitting areas being independently controllable and arranged to direct light towards at least one of a retina and an iris of the eye, causing an output beam from light backscattered from the at least one of the retina and the iris by the oblique illumination, capturing the output beam with an imaging system to provide a sequence of images of a fundus of the eye, and retrieving a phase and absorption contrast image from the sequence of images of the fundus, wherein the sequence of images of the fundus of the step of capturing is obtained by sequentially turning on one or more of the plurality of light emitting areas at a time in the step of providing the oblique illumination.

Abstract: An electroporation device for injecting a product into a ciliary muscle of an eye includes a support having a spherical support contact surface extending along a virtual sphere having a radius between 10 and 15 mm, a first electrode comprising a curved invasive electrode needle, a second electrode having an electrically conductive electrode contact surface, and an injection needle.

Abstract: The invention relates to a pharmaceutical formulation comprising a spironolactone and at least one polymer or a polymer mixture as well as its use in particular indications.

Abstract: An electroporation device for injecting a product into a ciliary muscle of an eye, said device comprising: a support having a support contact surface extending along a virtual sphere having a radius between 10 and 15 mm, so as to match the outside surface of the eye, a first electrode comprising an invasive electrode needle, a second electrode having an electrically conductive electrode contact surface, optionally an injection needle, wherein the support comprises an insertion guide configured to guide a sliding of said electrode needle and/or injection needle along a respective insertion axis, so that the angle between said insertion axis and a plane tangential to the virtual sphere at the insertion point is less than 40°, the insertion point being the point where said insertion axis crosses said virtual sphere.

Abstract: This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema.

Abstract: A method for imaging a tissue of an eye, the method including the steps of providing oblique illumination to the eye by a plurality of light emitting areas of a light delivery device, the plurality of light emitting areas being independently controllable and arranged to direct light towards at least one of a retina and an iris of the eye, causing an output beam from light backscattered from the at least one of the retina and the iris by the oblique illumination, capturing the output beam with an imaging system to provide a sequence of images of a fundus of the eye, and retrieving a phase and absorption contrast image from the sequence of images of the fundus, wherein the sequence of images of the fundus of the step of capturing is obtained by sequentially turning on one or more of the plurality of light emitting areas at a time in the step of providing the oblique illumination.

Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor.

Abstract: An electroporation device for injecting a product into a ciliary muscle of an eye, said device comprising: a support having a support contact surface extending along a virtual sphere having a radius between 10 and 15 mm, so as to match the outside surface of the eye, a first electrode comprising an invasive electrode needle, a second electrode having an electrically conductive electrode contact surface, optionally an injection needle, wherein the support comprises an insertion guide configured to guide a sliding of said electrode needle and/or injection needle along a respective insertion axis, so that the angle between said insertion axis and a plane tangential to the virtual sphere at the insertion point is less than 40°, the insertion point being the point where said insertion axis crosses said virtual sphere.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of choroidal neovascularisation. In particular, the present invention relates to a method of treating choroidal neovascularisation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a mineralocorticoid receptor antagonist.

Abstract: The present invention relates to the Transferrin (Tf) or an active fragment thereof for use in the treatment of retinal detachment and/or for use in the treatment of retinal detachment related to other diseases.

Abstract: An electrode device having an insertion part (12) adapted to be inserted into the suprachoroidal space of an eye so as to reach a service position, and an handling part (14) for manipulation of the electrode device, said electrode device comprising: —a support (25) having a distal part (31); —a set of wires (20) supported by said support and mobile between a retracted position in which said wires substantially extend along the support, and a deployed position in which respective parts of said wires, called “outside parts”, project from said distal part (31) of the support; —an electrically conductive element forming at least a portion of a said outside part or supported by a said outside part; —an electrical conductor (60) enabling, in said deployed position, an electrical connection between said electrically conductive element and an electrical generator; and —an actuator (16, 60) adapted for an operator to move the set of wires from said retracted position to said deployed position in said service position.

Abstract: Treatment of a disease associated with retinal degenerative disorder. The present invention relates to human Transferrin or an active fragment thereof for use in the treatment of a disease associated with retinal degenerative disorder.

Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.

Abstract: An injection device for injecting a product into an eye, said device comprising an injection needle and a support on which the injection needle is fixed, said device being characterized in that it comprises a locating mark disposed in such a way that the latter can be placed in contact with a defined bearing region of the surface of the eye, before any contact of the injection needle with said surface, and can then be kept in contact with said bearing region during a stage of penetration of said injection needle through said surface of the eye.